Sugi Predict

Sugi Predict / Compounds / SCHEMBL5265665

SCHEMBL5265665

SCHEMBL5265665

CNc1nc(OC)c(NC(=O)c2ccc(Cc3cc4c(cc3C)CC[Si]4(C)C)o2)c(OC)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GNRHR P30968 17/20 0.55
▸ FPR1 P21462 1/20 0.47
▸ GPR183 P32249 1/20 0.47
▸ GPR119 Q8TDV5 1/20 0.47
▸ CACNA1F O60840 1/20 0.39
▸ CHRM4 P08173 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ DRD1 P21728 1/20 0.39
▸ DRD4 P21917 1/20 0.39
▸ SLC6A2 P23975 1/20 0.39
▸ HRH2 P25021 1/20 0.39
▸ TACR1 P25103 1/20 0.39
▸ PTAFR P25105 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ HTR2C P28335 1/20 0.39
▸ AGTR1 P30556 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39
▸ HTR7 P34969 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5269071 0.92 GNRHR (0.51) GNRHRFPR1GPR183GPR119CACNA1F
SCHEMBL5268218 0.89 GNRHR (0.57) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL5267682 0.88 GNRHR (0.55) GNRHRFPR1GPR183GPR119CACNA1F
SCHEMBL5264900 0.87 GNRHR (0.51) GNRHRFPR1GPR183GPR119CACNA1F
SCHEMBL5264925 0.86 GNRHR (0.54) GNRHRFPR1GPR183GPR119CACNA1F
SCHEMBL5264645 0.85 GNRHR (0.59) GNRHRFPR1GPR183GPR119CACNA1F
SCHEMBL5267626 0.84 GNRHR (0.56) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL5265064 0.83 GNRHR (0.68) GNRHRFPR1GPR183GPR119ALDH1A1
SCHEMBL5264670 0.83 GNRHR (0.51) GNRHRFPR1GPR183GPR119CACNA1F
SCHEMBL5264070 0.83 GNRHR (0.57) GNRHRFPR1GPR183GPR119ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648906-B1 ORGANOSILICON COMPOUNDS AND THEIR USE TAKEDA CAMBRIDGE LTD (GB) 2007-10-03 — — EP claimed
US-20070111967-A1 Organosilicon compounds and their use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-17 — — US claimed
EP-1648906-B1 ORGANOSILICON COMPOUNDS AND THEIR USE TAKEDA CAMBRIDGE LTD (GB) 2007-10-03 — — EP disclosed
US-20070111967-A1 Organosilicon compounds and their use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-17 — — US disclosed
US-20070111967-A1 Organosilicon compounds and their use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-17 — — US disclosed
EP-1648906-A1 ORGANOSILICON COMPOUNDS AND THEIR USE Paradigm Therapeutics Limited (GB) 2006-04-26 — — EP disclosed
WO-2005005443-A1 ORGANOSILICON COMPOUNDS AND THEIR USE PARADIGM THERAPEUTICS LTD. (GB) 2005-01-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111967-A1 Organosilicon compounds and their use CYP2B6, UGT1A6, CYP2D6 GNRHR 2847/4885FPR1 509/4885GPR183 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.